The risk of clonal transformation to MDS/AML in patients with ASXL1, TP53, RUNX1, and DNMT3 variants is 40% higher than that in patients with PIGA, BCOR, and BCORL1 variants (13). This evidence concerns the gene ASXL1 and myelodysplastic syndrome.